TransMedics Expands Team with New Stock Option Grants for Employees

In a strategic move to bolster its workforce, TransMedics Group, Inc. has announced a series of inducement grants intended for its employees. On July 29, 2026, the medical technology company, renowned for revolutionizing organ transplantation therapy, revealed the granting of non-qualified stock options totaling 18,762 shares. Additionally, the company has allocated 12,414 restricted stock units to a group of 9 employees. These grants are a key incentive for the employees joining the organization, aiming to enhance loyalty and performance.

The Compensation Committee of the TransMedics Board of Directors approved these grants, which comply with NASDAQ Listing Rule 5635(c)(4). The option grants come with an exercise price of $78.00 per share, reflecting the closing stock price on the day of the grant. This strategic approach not only signifies TransMedics' commitment to rewarding its employees but also aligns with the company’s broader goals of attracting and retaining top talent in the medical technology sector.

Understanding the Vesting Structure

The terms of the grants establish a structured vesting process. Specifically, 25% of the shares associated with each stock option are scheduled to vest on the anniversary of the employees’ start date. Subsequently, the remaining shares will vest in equal monthly installments over the following three years, contingent on the employees’ sustained service with TransMedics. This structure is designed to encourage long-term commitment and ensure that employees remain engaged with the organization’s objectives.

The stock options will have a tenure of ten years, providing employees ample time to benefit from their grants provided they continue their employment. Likewise, the restricted stock units will vest over the first four anniversaries of the start date, reinforcing the value of stability and commitment within the company's workforce.

About TransMedics Group, Inc.

Based in Andover, Massachusetts, TransMedics is recognized as a leader in portable extracorporeal warm perfusion. The company specializes in the assessment and preservation of donor organs, thus enhancing the quality of transplants available for individuals suffering from end-stage heart, lung, and liver failures. With a mission aimed at addressing the critical shortage of viable organs, TransMedics is at the forefront of innovative medical technologies that significantly improve transplant outcomes.

This latest announcement fits within TransMedics' broader strategy of ensuring that the best possible care and technology are available for organ transplants. The company has developed groundbreaking techniques that not only preserve organ viability before transplants but are also intended to increase the utilization of donor organs, a critical need in the realm of organ transplantation.

Conclusion

TransMedics’ proactive efforts to foster employee engagement through strategic grants is a commendable approach that aligns employees’ interests with organizational success. As the company continues to innovate within the medical technology landscape, initiatives like these are likely to play a significant role in attracting top-tier talent dedicated to improving the lives of patients in need of transplant therapies.